-
Home > Resources > References
References
-
References
-
GLYX-13 and GFPA NMDA Modulators
Burgdorf, J., Zhang, X. L., Weiss, C., Matthews, E., Disterhoft, J. F., Stanton, P. K., & Moskal, J. R. (2009). The N-methyl-d-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats. Neurobiol Aging, in press.
Haring, R., Stanton, P.K., Scheideler, M., and Moskal, J.R. (1991) Glycine-like modulation of NMDA receptors by a monoclonal antibody that enhances long-term potentiation. J. Neurochem., 57: 323-332. (First report showing a monoclonal antibody enhancing learning and memory formation and its mechanism of action)
Moskal, J. R., Kuo, A. G., Weiss, C., Wood, P. L., O'Connor Hanson, A., Kelso, S., Harris, R. B., & Disterhoft, J. F. (2005). GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator. Neuropharmacology, 49(7), 1077-108
Moskal, J.R, J.R. Kuo, A.G, Weiss, C., Kelso, S., O'Connor Hanson, A., Wood, P.L., and Disterhoft, J.F. (2005) Glyxins: monoclonal antibody-derived peptides that act as partial agonists at the glycine site of the N-methyl-D-aspartate receptor. Neuropharmacology 49: 1077-1087. (Describes the conversion of a monoclonal antibody into a small peptide mimetic with cognitive enhancing properties)
Moskal, J.R., Yamamoto, H., and Colley, P.A. (2001) The use of antibody engineering to create novel drugs that target N-methyl-D-aspartate receptors. Current Drug Targets. 2: 331-345. (Review of GLYX-13 & its creation from a monoclonal antibody with NMDA receptor, glycine site-specific partial antagonist properties)
Moskal, J.R. and Schaffner, A.E. (1986) Monoclonal antibodies to the dentate gyrus: Immunocytochemical characterization and flow cytometric analysis of hippocampal neurons bearing unique cell-surface antigen. J. Neurosci., 6(7): 2045-2053. (Seminal publication of original monoclonal antibody work)
Stanton, P.K., Sarvey, J.M., and Moskal, J.R. (1987) Inhibition of the production and maintenance of long-term potentiation in rat hippocampal slices by a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 84:1684-1688. (First report showing modulation of learning and memory using a monoclonal antibody)
Thompson, L.T., Moskal, J.R., and Disterhoft, J.F. (1992) Hippocampus-dependent learning facilitated by a monoclonal antibody or D-cycloserine. Nature 359: 638-641. (First report showing monoclonal antibody enhancement of learning and memory in an animal model)
Wood, P.L., Mahmood, S.A., Moskal, J.R. (2008) Antinociceptive action of GLYX-13: an NMDA receptor glycine site partial agonist. Neuroreport. 2008 Jul 2; 19(10):1059-61. (First publication of GLYX-13 general NMDA properties relative to known other NMDA programs; and in vivo antinociceptive models comparable to FDA approved neuropathic pain drug, gabapentin)
Zhang, X. L., Sullivan, J. A., Moskal, J. R., & Stanton, P. K. (2008). A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology, 55(7), 1238-1250.
Zhang, X.L., Moskal, J.R., and Stanton, P.K. (2008) GLYX-13, a peptide partial agonist at the NMDA receptor glycine site, simultaneously enhances LTP and depresses LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology. 2008 Dec; 55(7):1238-50. (First evidence of GLYX-13 unique mechanism of action: showing ability to increase LTP and decrease LTD)
Other NMDA Receptor Modulator References
Burgdorf, J., Knutson, B., Panksepp, J., & Shippenberg, T. S. (2001). Evaluation of rat ultrasonic vocalizations as predictors of the conditioned aversive effects of drugs. Psychopharmacology, 155(1), 35-42.
de Bruin, N. M., Ellenbroek, B. A., Cools, A. R., Coenen, A. M., & van Luijtelaar, E. L. (1999). Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berl), 142(1), 9-17.
Garcia, L. S., Comim, C. M., Valvassori, S. S., Reus, G. Z., Barbosa, L. M., Andreazza, A. C., Stertz, L., Fries, G. R., Gavioli, E. C., Kapczinski, F., & Quevedo, J. (2008). Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry, 32(1), 140-144.
Skolnick P, Popik P, Trullas R., (2009) Glutamate-based antidepressants: 20 years on, Trends Pharmacol Sci. Nov; 30 (11):563-9. (Reviews the NMDA receptor hypothesis in depression, including multiple studies providing clinical proof-of-concept data for a number of NMDA receptor molecules.)
van der Kam, E. L., De Vry, J., & Tzschentke, T. M. (2009). 2-Methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates ketamine and heroin reward as assessed by acquisition, extinction, and reinstatement of conditioned place preference in the rat. Eur J Pharmacol, 606(1-3), 94-101.
